Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 301.3K | $2.0M | 4.28% | +37.2K | 2026-06-30 |
| BlackRock, Inc. | 109.4K | -- | 1.56% | +6.6K | 2026-06-30 |
| VANGUARD FIDUCIARY TRUST CO | 45.8K | -- | 0.65% | +6.2K | 2026-06-30 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 41.2K | -- | 0.59% | -- | 2026-06-30 |
| STATE STREET CORP | 35.4K | -- | 0.50% | -- | 2026-06-30 |
| UBS Group AG | 33.4K | -- | 0.47% | +26.9K | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES LLC | 33.1K | -- | 0.47% | -3.8K | 2026-06-30 |
| CITADEL ADVISORS LLC | 27.5K | -- | 0.39% | +14.8K | 2026-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 20.9K | -- | 0.30% | -- | 2026-06-30 |
| Ashton Thomas Private Wealth, LLC | 18.5K | -- | 0.26% | +493 | 2026-06-30 |
